Clinical trial · Interventional
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
NCT02576327CI-TRIAL-00025308unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Vomiting | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aprepitant | Drug | — | UNRESOLVED |
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Tropisetron | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Aprepitant Arm
- description
- Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）+ Aprepitant125mg（Day1-2）、80mg（Day3-6）
- interventionNames
- Drug: Tropisetron
- Drug: Dexamethasone
- Drug: Aprepitant
- type
- ACTIVE_COMPARATOR
- label
- Control Arm
- description
- Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）
- interventionNames
- Drug: Tropisetron
- Drug: Dexamethasone
Primary outcomes (1)
- measure
- Overall complete response (no emesis and no rescue therapy)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Men and women \>/= 18 years, \<65 years * Patients with lymphoma receiving autologous hematopoietic stem cell transplantation for the first time * ECOG 0-2 * TBIL,AST and ALT \< 2.5-fold upper normal range * Female and male subjects of childbearing potential must agree to use a medically accepted method of adequate contraception. * Signed informed consent Exclusion Criteria: * Prior autologous/ allogeneic hematopoietic stem cell transplantation for lymphoma * Women who are pregnant or breast feeding. * Serious or uncontroled infection * Serious complications * Severe renal or hepatic disease * Severe mental or nervous system diseases
References
Publications (0)
Data not yet available
No reference posted for this study.